Adrian Curran
Overview
Explore the profile of Adrian Curran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailon L, Molto J, Curran A, Cadinanos J, Carlos Lopez Bernaldo de Quiros J, de Los Santos I, et al.
Nat Commun
. 2025 Mar;
16(1):2146.
PMID: 40038256
Building on results from the AELIX-002 trial with HIVACAT T-cell immunogen (HTI)-based vaccines, the AELIX-003 (NCT04364035) trial tested the safety of the combination of ChAdOx1.HTI (C) and MVA.HTI (M), with...
2.
Kolossvary M, Schnittman S, Zanni M, Fitch K, Fichtenbaum C, Aberg J, et al.
JAMA Cardiol
. 2024 Dec;
10(3):254-264.
PMID: 39661372
Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene...
3.
Sanchez-Gaona N, Gallego-Cortes A, Astorga-Gamaza A, Rallon N, Benito J, Ruiz-Mateos E, et al.
JCI Insight
. 2024 Sep;
9(20).
PMID: 39288262
Elite controllers (ECs), a unique group of people with HIV (PWH), exhibit remarkable control of viral replication in the absence of antiretroviral therapy. In this study, we comprehensively characterized the...
4.
G Garcia-Ruiz De Morales A, Vivancos M, de Lagarde M, Ramirez Schacke M, Del Mar Arcos Rueda M, Orviz E, et al.
Lancet HIV
. 2024 Jun;
11(7):e470-e478.
PMID: 38824937
Background: Ending AIDS by 2030 requires improvements across all stages of the HIV care continuum. We used a longitudinal approach to assess changes in the HIV care continuum in Spain...
5.
Moyle G, Assoumou L, de Castro N, Post F, Curran A, Rusconi S, et al.
Lancet HIV
. 2024 Feb;
11(3):e156-e166.
PMID: 38417976
Background: The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to...
6.
Ambrosioni J, Diaz N, Marzolini C, Dragovic G, Imaz A, Calcagno A, et al.
Infect Dis Ther
. 2024 Feb;
13(3):609-617.
PMID: 38372897
Introduction: The objective was to characterize real-world outcomes of drug-drug interactions (DDIs) between antiretrovirals (ARVs) and other drugs, including over-the-counter medications (OTC), and treatment outcomes in clinical practice. Methods: www.clinicalcasesDDIs.com...
7.
Martin-Iguacel R, Moreno-Fornes S, Bruguera A, Aceiton J, Nomah D, Gonzalez-Cordon A, et al.
Clin Microbiol Infect
. 2024 Feb;
30(5):674-681.
PMID: 38342439
Objectives: To assess the effect of COVID-19 on the postacute risk of cardiovascular events (CVEs) among people with HIV (PWH). Methods: Population-based matched cohort, including all PWH ≥16 years in...
8.
Suarez-Garcia I, Gutierrez F, Perez-Molina J, Moreno S, Aldamiz T, Valencia Ortega E, et al.
J Cancer Res Clin Oncol
. 2023 Nov;
149(20):18161-18171.
PMID: 38008809
Purpose: Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH), to compare it with that of the general population, and to assess potential risk...
9.
Nadal-Baron P, Trejo-Zahinos J, Garcia J, Salmeron P, Sulleiro E, Arando M, et al.
Sex Transm Infect
. 2023 Oct;
99(8):520-526.
PMID: 37802652
Objectives: Culture of remains essential for antimicrobial resistance (AMR) surveillance. We evaluated the effect of time of specimen collection on culture yield following a positive nucleic acid amplification test (NAAT)....
10.
Astorga-Gamaza A, Perea D, Sanchez-Gaona N, Calvet-Mirabent M, Gallego-Cortes A, Grau-Exposito J, et al.
Cell Rep Med
. 2023 Sep;
4(10):101202.
PMID: 37741278
Human immunodeficiency virus (HIV) infection induces immunological dysfunction, which limits the elimination of HIV-infected cells during treated infection. Identifying and targeting dysfunctional immune cells might help accelerate the purging of...